1520 related articles for article (PubMed ID: 17699802)
1. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
2. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
3. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
4. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
[TBL] [Abstract][Full Text] [Related]
5. Predictors of relapse rate in MS clinical trials.
Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
[TBL] [Abstract][Full Text] [Related]
6. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
Ozakbas S; Ormeci B; Idiman E
J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
[TBL] [Abstract][Full Text] [Related]
7. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation.
Veugelers PJ; Fisk JD; Brown MG; Stadnyk K; Sketris IS; Murray TJ; Bhan V
Mult Scler; 2009 Nov; 15(11):1286-94. PubMed ID: 19965558
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with the risk of secondary progression in multiple sclerosis.
Koch M; Uyttenboogaart M; van Harten A; De Keyser J
Mult Scler; 2008 Jul; 14(6):799-803. PubMed ID: 18573840
[TBL] [Abstract][Full Text] [Related]
9. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
10. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
[TBL] [Abstract][Full Text] [Related]
11. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
13. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
14. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
15. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
[TBL] [Abstract][Full Text] [Related]
16. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
[TBL] [Abstract][Full Text] [Related]
17. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.
Young PJ; Lederer C; Eder K; Daumer M; Neiss A; Polman C; Kappos L;
Neurology; 2006 Sep; 67(5):804-8. PubMed ID: 16966541
[TBL] [Abstract][Full Text] [Related]
18. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
Zephir H; de Seze J; Duhamel A; Debouverie M; Hautecoeur P; Lebrun C; Malikova I; Pelletier J; Sénéchal O; Vermersch P
J Neurol Sci; 2004 Mar; 218(1-2):73-7. PubMed ID: 14759636
[TBL] [Abstract][Full Text] [Related]
19. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
Río J; Nos C; Tintoré M; Borrás C; Galán I; Comabella M; Montalban X
Ann Neurol; 2002 Oct; 52(4):400-6. PubMed ID: 12325067
[TBL] [Abstract][Full Text] [Related]
20. New natural history of interferon-beta-treated relapsing multiple sclerosis.
Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
